The largest randomized trial to date evaluating cerebral embolic protection (CEP) during TAVI showed no significant impact of CEP on post-procedural cognitive function.
Cognitive assessment using the telephone version of the Montreal Cognitive Assessment (t-MoCA) revealed small improvements post-TAVI in both groups with no between-group differences.
The incidence of clinically meaningful cognitive decline (≥3-point drop in t-MoCA) was similar between patients treated with CEP devices and controls.
Findings were consistent across multiple patient subgroups and robust to sensitivity analyses.
